Hidradenitis suppurativa improvement shown with lutikizumab

Phase 2 trial results found lutikizumab was efficacious in treating hidradenitis suppurativa in patients who had previously failed anti-tumor necrosis factor therapy, AbbVie announced in a press release.
The 16-week, double blind, parallel group, placebo-controlled, dose-ranging phase 2 study evaluated lutikizumab, a dual variable domain interleukin-1alpha/1beta antagonist, in 153 patients with HS who had previously failed anti-tumor necrosis factor therapy and who had moderate to severe disease.
Subjects were randomly assigned to receive lutikizumab 100 mg every other week, lutikizumab 300 mg

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart